Literature DB >> 17154402

Sustained Epstein-Barr virus detection in paediatric liver transplantation. Insights into the occurrence of late PTLD.

Lorenzo D'Antiga1, Monica Del Rizzo, Carlo Mengoli, Umberto Cillo, Graziella Guariso, Lucia Zancan.   

Abstract

Epstein-Barr virus (EBV) infection is the main cause of post-transplant lymphoproliferative disease (PTLD). Little is known on chronic carrier state and its relation with late PTLD. We aimed to study EBV infection in the long-term after paediatric liver transplantation (OLT). We conducted a retrospective review of 34 children monitored for a median of 5.8 years (range 1.5-17.7). 21 were IgG seronegative (group A) and 13 seropositive (group B) before OLT. Primary infection was the appearance of VCA-IgM or VCA-IgG or Real-Time Polymerase Chain Reaction (RT-PCR) in patients previously IgG seronegative; positive VCA-IgM or EA-IgG or RT-PCR lasting longer than 6 months was defined sustained viral detection (SVD). 18/21 patients of group A had a primary infection at a median time of 3 months after transplant (0.5-60). 14/18 of group A and 0/13 of group B had a SVD (P < 0.0001). Viral loads greater than 500 copies/10(5) mononuclear cells occurred in 12/18 patients in group A and 0/13 patients in group B (P < 0.0001). The 3 patients who developed late PTLD (median time after OLT 47 months, range 15-121) were from group A, and presented with SVD before developing PTLD. In conclusion, EBV infection in seronegative patients at OLT is associated with greater viral loads and sustained viral detection. Late PTLD occurred only in naïve patients with markers of SVD. Three to 4 monthly long-term monitoring of EBV in pre-OLT naïve patients might help preventing the occurrence of late PTLD. (c) 2006 AASLD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17154402     DOI: 10.1002/lt.20958

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  6 in total

Review 1.  Viral surveillance and subclinical viral infection in pediatric kidney transplantation.

Authors:  Jodi M Smith; Vikas R Dharnidharka
Journal:  Pediatr Nephrol       Date:  2014-08-16       Impact factor: 3.714

Review 2.  Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder.

Authors:  Margaret L Gulley; Weihua Tang
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

Review 3.  Epstein-Barr virus: silent companion or causative agent of chronic liver disease?

Authors:  Mihaela Petrova; Victor Kamburov
Journal:  World J Gastroenterol       Date:  2010-09-07       Impact factor: 5.742

Review 4.  Laboratory assays for Epstein-Barr virus-related disease.

Authors:  Margaret L Gulley; Weihua Tang
Journal:  J Mol Diagn       Date:  2008-06-13       Impact factor: 5.568

5.  Persistent Epstein-Barr viral load in Epstein-Barr viral naïve pediatric heart transplant recipients: Risk of late-onset post-transplant lymphoproliferative disease.

Authors:  Bibhuti Das; Robert Morrow; Rong Huang; David Fixler
Journal:  World J Transplant       Date:  2016-12-24

6.  Seroprevalence of cytomegalovirus in donors & opportunistic viral infections in liver transplant recipients.

Authors:  Joy Varghese; S Subramanian; Mettu Srinivas Reddy; Naresh Shanmugam; G Balajee; Vijaya Srinivasan; Jayanthi Venkataraman; Rela Mohamed
Journal:  Indian J Med Res       Date:  2017-04       Impact factor: 2.375

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.